About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Apr 06, 2020...
A comprehensive review of published studies on gut microbiota, immunity and arthritis suggests that having a microbial imbalance may precede the development of spondyloarthritides and osteoarthritis.
The review, which was published in Seminars in Arthritis and Rheumatism, suggests a close connection between an impaired microbiota, the immune system and inflammatory arthritis.
“In this review, we presented data supporting the idea that dysbiosis via a close, dynamic and tightly regulated cross talk with gut-associated lymphoid tissue, governs the development of inflammatory arthropathies, such as rheumatoid arthritis, spondyloarthritis and osteoarthritis. It became clear that unfavorable dysbiosis-mediated immune alterations precede the development of these disorders suggesting causal relationships in this link,” wrote authors Alexander Kalinkovich of the Weizmann Institute of Science in Israel, and Gregory Livshits of Tel Aviv University.
https://www.weizmann-usa.org/news-media/news-releases/a-noninvasive-test-for-gut-inflammation/
Jan 24, 2022... REHOVOT, ISRAEL—January 24, 2022— Today, people suspected of having inflammatory bowel disease are often required to undergo a colonoscopy, an invasive procedure performed under anesthesia. A new method developed at the Weizmann Institute of Science in collaboration with the Sheba Medical Center at Tel Hashomer may offer a noninvasive alternative: detecting inflammation in the intestines by analyzing a fecal sample. In the future, stool testing might facilitate the diagnosis of disorders such as Crohn’s disease and ulcerative colitis and help monitor their course, as well as enable physicians to select the most appropriate therapy for each patient. The study’s findings are being published this week in the journal Gut.
Aug 04, 2022... REHOVOT, ISRAEL—August 4, 2022—The myriads of microbes in our gut, collectively termed the microbiome, are considered important to our health, but they can also harbor bacteria that contribute to inflammatory bowel disease or other disorders. Currently, however, it is impossible to target such disease-contributing bacteria without harming the surrounding beneficial microbes. Antibiotics kill friendly microbes along with the harmful ones, and in any event, they tend to trigger bacterial resistance and to have side effects. In a study published today in Cell, Weizmann Institute of Science researchers have demonstrated the feasibility of a potential therapy for killing inflammation-causing gut bacteria in a targeted manner: by using viruses that infect them.
Dec 05, 2022...
There is no cure for Crohn’s disease or ulcerative colitis, the two chronic inflammatory bowel diseases (IBD) that cause flareups of abdominal pain, diarrhea, fatigue, weight loss and even malnutrition.
Ulcerative colitis affects only the colon, while Crohn’s can attack any part of the digestive system.
Although scientists debate whether IBD is an autoimmune disorder, they agree that the painful inflammation is caused by an abnormal immune response to lifestyle triggers (such as diet) and environmental triggers (such as bacteria).
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
